Cellectis S.A.

Cellectis S.A. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Cellectis S.A. is not a good value stock. Cellectis S.A. is not a good growth stock. Cellectis S.A. is not very popular among insiders. Cellectis S.A. is a mediocre stock to choose.
Log in to see more information.
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome...
CLLS Fundamental Data by TradingView

News

Cellectis (NASDAQ:CLLS) Receives New Coverage from Analysts at StockNews.com
Cellectis (NASDAQ:CLLS) Receives New Coverage from Analysts at StockNews.com

Ticker Report StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS - Free Report) in a report issued on Tuesday. The firm issued a sell rating on the biotechnology company's stock. A number of...\n more…

StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)
StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)

Zolmax Analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS - Get Free Report) in a report issued on Tuesday. The brokerage set a "sell" rating on the biotechnology company's...\n more…

Monthly information on share capital and company voting rights
Monthly information on share capital and company voting rights

Globe Newswire (Article 223-16 of General Regulation of the French financial markets authority)PARIS, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...\n more…

Cellectis' Breakthrough in TNBC Therapy
Cellectis' Breakthrough in TNBC Therapy

TipRanks Financial Blog Cellectis SA (CLLS) has released an update. Cellectis SA, a leader in gene-editing biotechnology, has announced promising pre-clinical results for a new CAR T-cell ...\n more…

Cellectis publishes pre-clinical evidence MUC1 CAR T-cells reducing certain BC
Cellectis publishes pre-clinical evidence MUC1 CAR T-cells reducing certain BC

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

Globe Newswire NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the Company ) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...\n more…